

Eurinvest Flexible

Monthly report 29 March 2019

	R-Shares	I-Shares
NAV in EUR	96.07	96.42
MTD return	1.7%	1.7%
YTD return	3.6%	3.6%
Net AuM	EUR 11.	5m

Manager's comment

March has again been a positive month with a return of 1,7%, even though we have kept our cautious stance on the markets. We have increased our global equity exposure to quality stocks, but have put hedging strategies on the main equity indices).

All in all, our global equity exposure has remained unchanged at 43%. Our US equity exposure is higher than in Europe as we see more potential in the US and potential headwinds in Europe (Brexit, european elections,..).

In bonds, we have increased our expousre to 20% as we have added a fund ($\operatorname{Mirabeaud}$ Galloway) invested in high yielding emerging bonds (denominated in strong currencies). However, we stay away from european bonds as they do not offer enough yield.

Our Gold position has increased a bit and now around 7%.

The cash position has been reduced to 14% as we have increased the gross equity exposure


Fund Strategy

The strategy of the fun aims at offering a superior return thanks to flexible allocation throughout all liquid asset classes and use of derivatives for hedging purpose (no

The « average » equity allocation is 50% and can fluctuate in a «normal » frame between 40% and 60% and ultimately between 20% and 80%.

As from February 2019, this strategy is realized through long only funds and ETF's, on which we apply hedging strategies via listed derivatives.

Evolution of NAV class I Dis (€) vs. Benchmark (1)



ormance period (1)	Eurinvest Flexible (2)	Benchmark (3)	nce
March 2019	1.7%	2.7%	-1.0%
Year-to-date	5.4%	9.3%	-4.0%
2018	-7.8%	-0.3%	-7.5%
2017	-0.7%	1.8%	-2.6%

- (1) Weekly NAV; Source: Bloomberg Returns based on historical data, which offer no guarantee of future returns;
- est Flexible / I-Share (in EURO);
- (a) Eurowest Heabile /1-Share (in EURU);
 (3) Stook 600 Net Return Bloomberg ticker SXXR (in Euro) and MSCI World ex EMU Net Return Bloomberg ticker MSDEWEMN (in Euro) & Barkays Euro Aggregate Total Return Index Bloomberg ticker IBEATREU (in Euro) and JPM Global Aggregate Total Return Index Bloomberg ticker IBEATREU (in Euro). The investment policy of the subfund does not include a tracking error objective with the benchmark. Performances of the subfund may therefore

Asset Allocation ■ Equities Hedge Equities Net Bonds Others Cash



Equity Exposure



Fund facts

Fund name	EURINVEST Partners SA - F	EURINVEST Partners SA - Flexible		
Legal structure	Luxembourg SICAV-SIF	Luxembourg SICAV-SIF		
Custodian	ING Luxembourg			
Domicile	Luxembourg (regulated by	Luxembourg (regulated by the CSSF)		
Geography	World	World		
Asset classes	All	All		
Strategy	Long funds and ETFs; Listed	Long funds and ETFs; Listed derivatives for hedging		
Investment Manager	Eurinvest Partners SA	Eurinvest Partners SA		
Fund administrator	Vistra			
NAV Calculation	Weekly			
Assets under management	EUR 11.5m	EUR 11.5m		
Share class	R-Shares	I-Shares		
Management fee	90 bps	65 bps		
Performance fee	None	None		
Total Expense Ratio (TER)	1.95%	1.70%		
Minimum investment	EUR 250.000	EUR 500.000		
Liquidity	Weekly, 2 day notice	Weekly, 2 day notice		
TOB	None	None		
Share type	Capitalisation	Capitalisation		
ISIN	LU1650583302	LU1650583054		
Ticker Bloomberg	EIFLXCR LX	EIFLXCI LX		
Inception	31/10/2017	31/10/2017		

Main holdings of the portfolio

	1	Varenne Valeur	6.80%
Long	2	DB ETC on Gold	6.74%
	3	BL Equities Dividend	6.35%
	4	Prevoir Gestion Actions	5.80%
	5	Dimensional Global Short Fixed inc	5.74%
Short -	1	Hedge Short Futures Europe	-11.99%
	2	Hedge Short futures USA (mini S&P)	-3.54%
	3	Hedge Short Futures Asia Paciic	-0.88%
	4		
	5		

All information in this document about Eurimest Placebe the "Fund") has been prepared by Eurimest Placebe on the act 1, Bue de Maximum, Ed-24 Livemborg, Grand Dutyly of Livemborg, Grand Dutyly of Livemborg Commendation, Euripe Placebe and Dutyly of Livemborg Commendation and Eurimest Placebe on the Grand Dutyly of Livemborg Livemborg and Euripe Placebe and Livemborg Livembo